Studies beginning enrollment in 2010, compared with studies beginning enrollment before 2010, were more likely to specify tumor differentiation (59 studies [98%] vs 34 studies [63%]; P < .001), Ki-67 index (23 studies [38%] vs 4 studies [9%]; P < .001), and, among later-line studies, mandated disease progression at study entry (35 studies [67%] vs 18 studies [42%]; P = .01) in inclusion criteria. The gene discussed is MKI67; the disease is neoplasm.